A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence
Early attempts to improve BCG have focused on increasing the expression of prominent antigens and adding recombinant toxins or cytokines to influence antigen presentation. One such modified BCG vaccine candidate has been withdrawn from human clinical trials due to adverse effects. BCG was derived from virulent Mycobacterium bovis and retains much of its capacity for suppressing host immune responses. Accordingly, we have used a different strategy for improving BCG based on reducing its immune suppressive capacity. We made four modifications to BCG Tice to produce 4dBCG and compared it to the parent vaccine in C57Bl/6 mice. The modifications included elimination of the oxidative stress sigma factor SigH, elimination of the SecA2 secretion channel, and reductions in the activity of iron co-factored superoxide dismutase and glutamine synthetase. After IV inoculation of 4dBCG, 95% of vaccine bacilli were eradicated from the spleens of mice within 60 days whereas the titer of BCG Tice was not significantly reduced. Subcutaneous vaccination with 4dBCG produced greater protection than vaccination with BCG against dissemination of an aerosolized challenge of M. tuberculosis to the spleen at 8 weeks post-challenge. At this time, 4dBCG-vaccinated mice also exhibited altered lung histopathology compared to BCG-vaccinated mice and control mice with less well-developed lymphohistiocytic nodules in the lung parenchyma. At 26 weeks post-challenge, 4dBCG-vaccinated mice but not BCG-vaccinated mice had significantly fewer challenge bacilli in the lungs than control mice. In conclusion, despite reduced persistence in mice a modified BCG vaccine with diminished antioxidants and glutamine synthetase is superior to the parent vaccine in conferring protection against M. tuberculosis. The targeting of multiple immune suppressive factors produced by BCG is a promising strategy for simultaneously improving vaccine safety and effectiveness.
References
[1]
Fine, P.E.M.; Carneiro, I.A.M.; Milstien, J.B.; Clements, J.D. Issues Relating to the Use of BCG in Immunization Programs, a Discussion Document, Document WHO/V&B/99.23 ed; World Health Organization Department of Vaccines and Biologicals: Geneva, Switzerland, 1999.
[2]
Andersen, P.; Doherty, T.M. The success and failure of BCG—Implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 2005, 3, 656–662, doi:10.1038/nrmicro1211.
[3]
Behr, M.A.; Wilson, M.A.; Gill, W.P.; Salamon, H.; Schoolnik, G.K.; Rane, S.; Small, P.M. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284, 1520–1523, doi:10.1126/science.284.5419.1520.
[4]
Brosch, R.; Gordon, S.V.; Garnier, T.; Eiglmeier, K.; Frigui, W.; Valenti, P.; Dos, S.S.; Duthoy, S.; Lacroix, C.; Garcia-Pelayo, C.; et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. USA 2007, 104, 5596–5601.
[5]
Trunz, B.B.; Fine, P.; Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: A meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367, 1173–1180.
[6]
Bonifachich, E.; Chort, M.; Astigarraga, A.; Diaz, N.; Brunet, B.; Pezzotto, S.M.; Bottasso, O. Protective effect of Bacillus Calmette-Guérin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina. Vaccine 2006, 24, 2894–2899, doi:10.1016/j.vaccine.2005.12.044.
[7]
Bjartveit, K. Olaf Scheel and Johannes Heimbeck: Their contribution to understanding the pathogenesis and prevention of tuberculosis. Int. J. Tuberc. Lung Dis. 2003, 7, 306–311.
[8]
Aronson, J.D.; Aronson, C.F.; Taylor, H.C. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch. Intern. Med. 1958, 101, 881–893, doi:10.1001/archinte.1958.00260170037006.
[9]
Aronson, N.E.; Santosham, M.; Comstock, G.W.; Howard, R.S.; Moulton, L.H.; Rhoades, E.R.; Harrison, L.H. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004, 291, 2086–2091, doi:10.1001/jama.291.17.2086.
[10]
Behr, M.A.; Small, P.M. Has BCG attenuated to impotence? Nature 1997, 389, 133–134.
[11]
Kernodle, D.S. Decrease in the effectiveness of Bacille Calmette-Guérin vaccine against pulmonary tuberculosis: A consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin. Infect. Dis. 2010, 51, 177–184, doi:10.1086/653533.
[12]
Sadagopal, S.; Braunstein, M.; Hager, C.C.; Wei, J.; Daniel, A.K.; Bochan, M.R.; Crozier, I.; Smith, N.E.; Gates, H.O.; Barnett, L.; et al. Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG. PLoS One 2009, 4, e5531.
[13]
Horwitz, M.A.; Harth, G.; Dillon, B.J.; Maslesa-Galic’, S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 2000, 97, 13853–13858.
[14]
Grode, L.; Seiler, P.; Baumann, S.; Hess, J.; Brinkmann, V.; Eddine, A.N.; Mann, P.; Goosmann, C.; Bandermann, S.; Smith, D.; et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 2005, 115, 2472–2479, doi:10.1172/JCI24617.
[15]
Sun, R.; Skeiky, Y.A.; Izzo, A.; Dheenadhayalan, V.; Imam, Z.; Penn, E.; Stagliano, K.; Haddock, S.; Mueller, S.; Fulkerson, J.; et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27, 4412–4423.
Braunstein, M.; Espinosa, B.J.; Chan, J.; Belisle, J.T.; Jacobs, W.R., Jr. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol. Microbiol. 2003, 48, 453–464, doi:10.1046/j.1365-2958.2003.03438.x.
[18]
Hinchey, J.; Lee, S.; Jeon, B.Y.; Venkataswamy, M.M.; Chen, B.; Chan, J.; Braunstein, M.; Orme, I.M.; Derrick, S.C.; Morris, S.L.; et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Investig. 2007, 117, 2279–2288, doi:10.1172/JCI31947.
[19]
Jain, R.; Dey, B.; Khera, A.; Srivastav, P.; Gupta, U.D.; Katoch, V.M.; Ramanathan, V.D.; Tyagi, A.K. Over-expression of superoxide dismutase obliterates the protective effect of BCG against tuberculosis by modulating innate and adaptive immune responses. Vaccine 2011, 29, 8118–8125.
[20]
Kaushal, D.; Schroeder, B.G.; Tyagi, S.; Yoshimatsu, T.; Scott, C.; Ko, C.; Carpenter, L.; Mehrotra, J.; Manabe, Y.C.; Fleischmann, R.D.; et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative σ factor, SigH. Proc. Natl. Acad. Sci. USA 2002, 99, 8330–8335.
[21]
Mehra, S.; Golden, N.A.; Stuckey, K.; Didier, P.J.; Doyle, L.A.; Russell-Lodrigue, K.E.; Sugimoto, C.; Hasegawa, A.; Sivasubramani, S.K.; Roy, C.J.; et al. The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J. Infect. Dis. 2012, 205, 1203–1213, doi:10.1093/infdis/jis102.
[22]
Kernodle, D.S. SigH, antioxidants, and the pathogenesis of pulmonary tuberculosis. J. Infect. Dis. 2012, 205, 1186–1188, doi:10.1093/infdis/jis108.
[23]
Raynaud, C.; Etienne, G.; Peyron, P.; Laneelle, M.A.; Daffe, M. Extracellular enzyme activities potentially involved in the pathogenicity of Mycobacterium tuberculosis. Microbiology 1998, 144, 577–587, doi:10.1099/00221287-144-2-577.
[24]
Miller, B.H.; Shinnick, T.M. Evaluation of Mycobacterium tuberculosis genes involved in resistance to killing by human macrophages. Infect. Immun. 2000, 68, 387–390, doi:10.1128/IAI.68.1.387-390.2000.
[25]
Tullius, M.V.; Harth, G.; Horwitz, M.A. Glutamine synthetase GlnA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs. Infect. Immun. 2003, 71, 3927–3936.
[26]
Manganelli, R.; Voskuil, M.I.; Schoolnik, G.K.; Dubnau, E.; Gomez, M.; Smith, I. Role of the extracytoplasmic-function σ factor σH in Mycobacterium tuberculosis global gene expression. Mol. Microbiol. 2002, 45, 365–374, doi:10.1046/j.1365-2958.2002.03005.x.
[27]
Raman, S.; Song, T.; Puyang, X.; Bardarov, S.; Jacobs, W.R., Jr.; Husson, R.N. The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. J. Bacteriol. 2001, 183, 6119–6125, doi:10.1128/JB.183.20.6119-6125.2001.
[28]
Harth, G.; Maslesa-Galic, S.; Tullius, M.V.; Horwitz, M.A. All four Mycobacterium tuberculosis glnA genes encode glutamine synthetase activities but only GlnA1 is abundantly expressed and essential for bacterial homeostasis. Mol. Microbiol. 2005, 58, 1157–1172, doi:10.1111/j.1365-2958.2005.04899.x.
[29]
Dong, Y.; Demaria, S.; Sun, X.; Santori, F.R.; Jesdale, B.M.; de Groot, A.S.; Rom, W.N.; Bushkin, Y. HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect. Immun. 2004, 72, 2412–2415, doi:10.1128/IAI.72.4.2412-2415.2004.
[30]
Gill, H.S.; Pfluegl, G.M.; Eisenberg, D. Multicopy crystallographic refinement of a relaxed glutamine synthetase from Mycobacterium tuberculosis highlights flexible loops in the enzymatic mechanism and its regulation. Biochemistry 2002, 41, 9863–9872.
[31]
Milstien, J.B.; Gibson, J.J. Quality control of BCG vaccine by WHO: A review of factors that may influence vaccine effectiveness and safety. Bull. World Health Organ. 1990, 68, 93–108.
[32]
Ladefoged, A.; Bunch-Christensen, K.; Guld, J. Tuberculin sensitivity in guinea-pigs after vaccination with varying doses of BCG of 12 different strains. Bull. World Health Organ. 1976, 53, 435–443.
[33]
Kupferschmidt, K. Infectious disease. Taking a new shot at a TB vaccine. Science 2011, 334, 1488–1490, doi:10.1126/science.334.6062.1488.
[34]
Ottenhoff, T.H.; Kaufmann, S.H. Vaccines against tuberculosis: Where are we and where do we need to go? PLoS Pathog. 2012, 8, e1002607, doi:10.1371/journal.ppat.1002607.
[35]
Dubos, R.J.; Pierce, C.H. Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness. Am. Rev. Tuberc. 1956, 74, 699–717.
[36]
Dubos, R.J.; Pierce, C.H.; Schaefer, W.B. Differential characteristics in vitro and in vivo of several substrains of BCG. III. Multiplication and survival in vivo. Am. Rev. Tuberc. 1956, 74, 683–698.
[37]
Lagranderie, M.R.; Balazuc, A.M.; Deriaud, E.; Leclerc, C.D.; Gheorghiu, M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 1996, 64, 1–9.
[38]
Freudenstein, H.; Pranter, W.; Schweinsberg, H. Assessment of several BCG vaccines in different animal test systems (additional studies to an IABS collaborative assay). J. Biol. Stand. 1979, 7, 203–212.
[39]
Smith, D.; Harding, G.; Chan, J.; Edwards, M.; Hank, J.; Muller, D.; Sobhi, F. Potency of 10 BCG vaccines as evaluated by their influence on the bacillemic phase of experimental airborne tuberculosis in guinea-pigs. J. Biol. Stand. 1979, 7, 179–197, doi:10.1016/S0092-1157(79)80021-9.
[40]
Hank, J.A.; Chan, J.K.; Edwards, M.L.; Muller, D.; Smith, D.W. Influence of the virulence of Mycobacterium tuberculosis on protection induced by bacille Calmette-Guérin in guinea pigs. J. Infect. Dis. 1981, 143, 734–738, doi:10.1093/infdis/143.5.734.
[41]
Sekhuis, V.M.; Freudenstein, H.; Sirks, J.L. Report on results of a collaborative assay of BCG vaccines organized by the International Associaton of Biological Standardization. J. Biol. Stand. 1977, 5, 85–109.
[42]
Festjens, N.; Bogaert, P.; Batni, A.; Houthuys, E.; Plets, E.; Vanderschaeghe, D.; Laukens, B.; Asselbergh, B.; Parthoens, E.; de Rycke, R.; et al. Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. EMBO Mol. Med. 2011, 3, 222–234, doi:10.1002/emmm.201000125.
[43]
Saleh, M.T.; Belisle, J.T. Secretion of an acid phosphatase (SapM) by Mycobacterium tuberculosis that is similar to eukaryotic acid phosphatases. J. Bacteriol. 2000, 182, 6850–6853, doi:10.1128/JB.182.23.6850-6853.2000.
[44]
Vergne, I.; Chua, J.; Lee, H.H.; Lucas, M.; Belisle, J.; Deretic, V. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 2005, 102, 4033–4038.
[45]
Johansen, P.; Fettelschoss, A.; Amstutz, B.; Selchow, P.; Waeckerle-Men, Y.; Keller, P.; Deretic, V.; Held, L.; Kundig, T.M.; Bottger, E.C.; et al. Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens. Clin. Vaccine Immunol. 2011, 18, 907–913, doi:10.1128/CVI.00015-11.
Van der Veen, R.C.; Dietlin, T.A.; Karapetian, A.; Holland, S.M.; Hofman, F.M. Extra-cellular superoxide promotes T cell expansion through inactivation of nitric oxide. J. Neuroimmunol. 2004, 153, 183–189.
[48]
Pacheco, R.; Oliva, H.; Martinez-Navio, J.M.; Climent, N.; Ciruela, F.; Gatell, J.M.; Gallart, T.; Mallol, J.; Lluis, C.; Franco, R. Glutamate released by dendritic cells as a novel modulator of T cell activation. J. Immunol. 2006, 177, 6695–6704.
[49]
Gras, G.; Porcheray, F.; Samah, B.; Leone, C. The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. J. Leukoc. Biol. 2006, 80, 1067–1075, doi:10.1189/jlb.0306153.
[50]
Xue, H.; Field, C.J. New role of glutamate as an immunoregulator via glutamate receptors and transporters. Front. Biosci. (Schol. Ed.) 2011, 3, 1007–1020.
[51]
Jabs, T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem. Pharmacol. 1999, 57, 231–245, doi:10.1016/S0006-2952(98)00227-5.
[52]
Winau, F.; Kaufmann, S.H.; Schaible, U.E. Apoptosis paves the detour path for CD8 T cell activation against intracellular bacteria. Cell. Microbiol. 2004, 6, 599–607.
Jespersen, A. Use of red mice (Clethrionomys g. glareolus Schreb.) for estimation of the ability of vaccines to immunize against tuberculosis. Acta Pathol. Microbiol. Scand. 1954, 34, 157–160, doi:10.1111/j.1699-0463.1954.tb00812.x.
[56]
Jespersen, A. Studies on tuberculin sensitivity and immunity in guinea-pigs induced by vaccination with varying doses of BCG vaccine. Acta Pathol. Microbiol. Scand. 1956, 38, 203–210, doi:10.1111/j.1699-0463.1956.tb03168.x.
[57]
Jespersen, A.; Bentzon, M.W.; Magnusson, M. Development of tuberculin sensitivity and acquired resistance to tuberculosis in guinea pigs vaccinated with a small dose of BCG vaccine. Acta Pathol. Microbiol. Scand. 1962, 54, 291–304.
[58]
Ladefoged, A.; Bunch-Christensen, K.; Guld, J. The protective effect in bank voles of some strains of BCG. Bull. World Health Organ. 1970, 43, 71–90.
[59]
World Health Organization Department of Vaccines and Biologicals. Adverse Events Following BCG Vaccination, Chapter 2 in Clements, C. J., Supplementary Information on Vaccine Safety, Document WHO/V&B/00.36 ed; Geneva, Switzerland, 2000.
[60]
Gheorghiu, M.; Carnus, H.; Lagrange, P.; Chambon, L. Potency and suppurative adenitis in BCG vaccination. Dev. Biol. Stand 1978, 41, 79–84.
[61]
Bunch-Christensen, K.; Ladefoged, A.; Guld, J. The virulence of some strains of BCG for golden hamsters. Bull. World Health Organ. 1968, 39, 821–828.
[62]
Bunch-Christensen, K.; Ladefoged, A.; Guld, J. The virulence of some strains of BCG for golden hamsters. Further studies. Bull. World Health Organ. 1970, 43, 65–70.
[63]
Smith, D.W.; Wiegeshaus, E.; Navalkar, R.; Grover, A.A. Host-parasite relationships in experimental airborne tuberculosis. I. Preliminary studies in BCG-vaccinated and nonvaccinated animals. J. Bacteriol. 1965, 91, 718–724.
[64]
Jeon, B.Y.; Derrick, S.C.; Lim, J.; Kolibab, K.; Dheenadhayalan, V.; Yang, A.L.; Kreiswirth, B.; Morris, S.L. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun. 2008, 76, 5173–5180, doi:10.1128/IAI.00019-08.
[65]
Rhoades, E.R.; Frank, A.A.; Orme, I.M. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber. Lung Dis. 1997, 78, 57–66, doi:10.1016/S0962-8479(97)90016-2.
[66]
Albina, J.E. On the expression of nitric oxide synthase by human macrophages. Why no NO? J. Leukoc. Biol. 1995, 58, 643–649.
[67]
Dutta, N.K.; Mehra, S.; Didier, P.J.; Roy, C.J.; Doyle, L.A.; Alvarez, X.; Ratterree, M.; Be, N.A.; Lamichhane, G.; Jain, S.K.; et al. Genetic requirements for the survival of tubercle bacilli in primates. J. Infect. Dis. 2010, 201, 1743–1752, doi:10.1086/652497.
[68]
Tsai, M.C.; Chakravarty, S.; Zhu, G.; Xu, J.; Tanaka, K.; Koch, C.; Tufariello, J.; Flynn, J.; Chan, J. Characterization of the tuberculous granuloma in murine and human lungs: Cellular composition and relative tissue oxygen tension. Cell. Microbiol. 2006, 8, 218–232.
[69]
Gonzalez-Juarrero, M.; Turner, O.C.; Turner, J.; Marietta, P.; Brooks, J.V.; Orme, I.M. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 2001, 69, 1722–1728.
[70]
Khader, S.A.; Guglani, L.; Rangel-Moreno, J.; Gopal, R.; Junecko, B.A.; Fountain, J.J.; Martino, C.; Pearl, J.E.; Tighe, M.; Lin, Y.Y.; et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J. Immunol. 2011, 187, 5402–5407.
[71]
Ober, W.B. Ghon but not forgotten: Anton Ghon and his complex. Pathol. Annu. 1983, 18, 79–85.
[72]
Pathan, A.A.; Wilkinson, K.A.; Wilkinson, R.J.; Latif, M.; McShane, H.; Pasvol, G.; Hill, A.V.; Lalvani, A. High frequencies of circulating IFN-γ-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. Eur. J. Immunol. 2002, 30, 2713–2721.
[73]
Tully, G.; Kortsik, C.; Hohn, H.; Zehbe, I.; Hitzler, W.E.; Neukirch, C.; Freitag, K.; Kayser, K.; Maeurer, M.J. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J. Immunol. 2005, 174, 2174–2184.
[74]
Carranza, C.; Juarez, E.; Torres, M.; Ellner, J.J.; Sada, E.; Schwander, S.K. Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. Am. J. Respir. Crit. Care Med. 2006, 173, 238–245.
[75]
Irvine, K.N. B.C.G. Vaccination in Theory and Practice; Blackwell Scientific Publications, Ltd.: London and Oxford, UK, 1949.
[76]
Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention: First report. Bull. World Health Organ. 1979, 57, 819–827.
[77]
Comstock, G.W. Identification of an effective vaccine against tuberculosis. Am. Rev. Respir. Dis. Epidemiol. Rev. 1988, 138, 479–480.
[78]
Comstock, G.W. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol. Rev. 1994, 16, 77–89.
[79]
Comstock, G.W. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine. Clin. Infect. Dis. 2000, 30, S250–S253, doi:10.1086/313870.
[80]
Favorov, M.; Ali, M.; Tursunbayeva, A.; Aitmagambetova, I.; Kilgore, P.; Ismailov, S.; Chorba, T. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan. PLoS One 2012, 7, e32567.
[81]
Dubos, R.J.; Pierce, C.H. Differential characteristics in vitro and in vivo of several substrains of BCG. I. Multiplication and survival in vitro. Am. Rev. Tuberc. 1956, 74, 655–666.
[82]
Oettinger, T.; Jorgensen, M.; Ladefoged, A.; Haslov, K.; Andersen, P. Development of the Mycobacterium bovis BCG vaccine: Review of the historical and biochemical evidence for a genealogical tree. Tuber. Lung Dis. 1999, 79, 243–250, doi:10.1054/tuld.1999.0206.
Kernodle, D.S.; Bochan, M.R. Pro-apoptotic bacterial vaccines to enhance cellular immune responses (United States Patent no. 8,021,671; World Intellectual Property Organization publication No. WO/2002/062298. Available online: http://patentscope.wipo.int/search/en/WO2002062298/ (accessed on 18 December 2012).
[85]
Kernodle, D.S. Warning: Differences in the copy number of duplication unit 2 (DU2) within BCG Danish 1331 may influence findings involving genetically modified BCG Danish strains. Vaccine 2012, 30, 6013–6014, doi:10.1016/j.vaccine.2012.01.023.
[86]
Palanisamy, G.S.; Smith, E.E.; Shanley, C.A.; Ordway, D.J.; Orme, I.M.; Basaraba, R.J. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis (Edinb.) 2008, 88, 295–306, doi:10.1016/j.tube.2007.12.003.
[87]
Hanahan, D. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 1983, 166, 557–580, doi:10.1016/S0022-2836(83)80284-8.
[88]
Braunstein, M.; Bardarov, S.S.; Jacobs, W.R., Jr. Genetic methods for deciphering virulence determinants of Mycobacterium tuberculosis. Meth. Enzymol. 2002, 358, 67–99, doi:10.1016/S0076-6879(02)58081-2.
[89]
Ho, S.N.; Hunt, H.D.; Horton, R.M.; Pullen, J.K.; Pease, L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989, 77, 51–59, doi:10.1016/0378-1119(89)90358-2.
[90]
Woolfolk, C.A.; Shapiro, B.; Stadtman, E.R. Regulation of glutamine synthetase. I. Purification and properties of glutamine synthetase from Escherichia coli. Arch. Biochem. Biophys. 1966, 116, 177–192, doi:10.1016/0003-9861(66)90026-9.
